Nectar Lifesciences Buyback 2025 vs Nureca Limited Buyback 2025

Comparison between Nectar Lifesciences Buyback 2025 and Nureca Limited Buyback 2025.

Buyback Details

Nectar Lifesciences Buyback 2025 is a Tender Offer buyback proposed to list at BSE, NSE while Nureca Limited Buyback 2025 is a Tender Offer proposed to list at BSE, NSE.

 Nectar Lifesciences Ltd.Nureca Ltd.
LogoNectar Lifesciences Buyback 2025 LogoNureca Limited Buyback 2025 Logo
Type of BuybackTender OfferTender Offer
Listing AtBSE, NSEBSE, NSE
Face Value₹1 per share₹10 per share
Buyback Price₹27 per share₹330 per share
Issue Size3,00,00,000 shares5,80,000 shares
Issue Size (Amount)₹81.00 Crores₹19.14 Crores
Buyback Ratio
CategoryEntitlement Ratio of BuybackShares Offered
Reserved Category for Small Shareholders25 Equity Shares out of every 103 Fully paid-up Equity Shares held on the Record Date.1,32,51,651
General Category for all other Eligible Shareholders25 Equity Shares out of every 103 Fully paid-up Equity Shares held on the Record Date.1,67,48,349
CategoryEntitlement Ratio of BuybackShares Offered
Reserved Category for Small Shareholders126 Equity Shares out of every 761 Fully paid-up Equity Shares held on the Record Date.3,29,093
General Category for all other Eligible Shareholders126 Equity Shares out of every 761 Fully paid-up Equity Shares held on the Record Date.2,50,907
RegistrarKfin Technologies Ltd.Alankit Assignments Ltd.
Lead ManagersMaster Capital Services Ltd.Mefcom Capital Markets Ltd.
Necessity of the buyback
  • The buyback will help the company to return surplus cash to its shareholders holding equity shares broadly in proportion to their shareholding, thereby, enhancing the overall return to shareholders.
  • The buyback will help the company to optimize the capital structure;
  • The Buyback, which is being implemented through the Tender Offer route as prescribed under the SEBI Buyback Regulations, would involve allocation of the number of equity shares as per their entitlement or 15% of the number of equity shares to be bought back, whichever is higher, reserved. The company believes that the reservation for small shareholders would benefit a large number of the Company's public shareholders, who get classified as "Small Shareholders, as per regulations 2(i)(n) of the SEBI Buyback Regulations.
  • The buyback may help in improving financial ratios like earnings per share, return on capital employed, and return on equity, by reduction in the equity base, thereby leading to long-term increase in shareholders' vlaue; and
  • The buyback gives an option to the shareholders holding Equity shares of the company, who can choose to participate and get cash in lieu of Equity shares to be accepted under the Buyback offer or they may choose not to participate and enjoy a resultant increase in their percentage shareholding, post the buyback offer, without additional investment.

The Company is undertaking the Buyback after taking into account the Company's medium-term strategic and operational cash requirements, as well as the need to return surplus funds to the members in an effective and efficient manner. The proposed Buyback will help the Company achieve the following objectives:

  1. Optimise returns to shareholders; and
  2. Enhance overall shareholders' value. 2.2 The above objectives will be achieved through the Buyback process. They may lead to reduction in outstanding Equity Shares, improvement in earnings per Equity Share and enhanced return on invested capital. The Buyback will not, in any manner, impair the Company's ability to pursue growth opportunities or meet its cash requirements for business operations and continued capital investment, as and when required.
  3. The Buyback will help the Company to return surplus cash to its shareholders holding Equity Shares broadly in proportion to their shareholding, thereby, enhancing the overall return to shareholders;
  4. The Buyback, which is being implemented through the Tender Offer route as prescribed under the Buyback Regulations, would involve a reservation of up to 15% of the Equity Shares proposed to be brought back by the Company or the actual number of Equity Shares entitled as per the shareholding of small shareholders on the Record Date, whichever is higher. The Company believes that this reservation for small shareholders would benefit a significant number of the Company's public shareholders, who would be classified as 'Small Shareholders';
  5. The Buyback may help in improving return on equity, earnings per share by reduction in the equity base in the long term, thereby leading to long-term increase in shareholders' value; and
  6. The Buyback gives an option to the Eligible Shareholders to either (A) participate in the Buyback and receive cash in lieu of their Equity Shares, which are accepted under the BuyBack offer or (B) not to participate in the Buyback offer and get a resultant increase in their percentage shareholding in the Company post the BuyBack offer, without additional investment.

Buyback Timetable

Nectar Lifesciences Buyback 2025 and Nureca Limited Buyback 2025 buyback timetable. The investors should have the company's shares in their demat accounts as of the record date. Nectar Lifesciences Buyback 2025 Buyback record date is Dec 24, 2025. Nureca Limited Buyback 2025 Buyback record date is Dec 12, 2025.

 Nectar Lifesciences Ltd.Nureca Ltd.
Record DateDec 24, 2025Dec 12, 2025
Offer Open DateDec 31, 2025Dec 18, 2025
Offer Closure DateJan 06, 2026Dec 24, 2025
Last date for receipt of tender formsJan 06, 2026Dec 24, 2025
Finalisation of buybackJan 12, 2026Dec 30, 2025
Last Date for settlment of bidsJan 13, 2026Jan 01, 2026
Last Date for extinguishment of sharesJan 22, 2026Jan 12, 2026

Financial Details and Other Relevent Information

Comparison of Nectar Lifesciences Buyback 2025 and Nureca Limited Buyback 2025 financial data. The table below also includes a list of all relevant information like Stock Market Data, Compay Information, Lead Manager and Registrar.

 Nectar Lifesciences Ltd.Nureca Ltd.
Financial

Company Financials (Restated Consolidated)

Nectar Lifesciences Ltd.'s revenue decreased by 1% and profit after tax (PAT) dropped by 2376% between the financial year ending with March 31, 2025 and March 31, 2024.

Period Ended30 Sep 202531 Mar 202531 Mar 202431 Mar 2023
Total Income11.301,674.971,698.661,566.85
Profit After Tax-1.01-113.684.99-24.18
NET Worth716.87956.111,069.251,064.59
Reserves and Surplus694.44933.681,046.821,042.17
Total Borrowing458.85582.02635.54753.83
Amount in ₹ Crore

Nureca Limited Financial (Restated Consolidated)

Nureca Limited's revenue increased by 19% and profit after tax (PAT) rose by 147% between the financial year ending with March 31, 2025 and March 31, 2024.

Period Ended31 Mar 202531 Mar 202431 Mar 2023
Total Income122.10102.44118.43
Profit After Tax0.85-1.79-8.25
Amount in ₹ Crore
Stock price at BSE

Stock price at BSE (in preceding 3 months)

Month High Price Low Price Average Price
Nov-2025 16.99 13.75 14.67
Oct-2025 16.01 13.31 14.26
Sep-2025 17.03 14.07 15.15

Stock price at BSE (in preceding 3 months)

Month High Price Low Price Average Price
Jan-2025 294.50 245.00 268.88
Jan-2025 343.60 225.85 263.56
Jan-2025 278.40 225.95 246.70
Stock price at NSE

Stock price at NSE (in preceding 3 months)

Month High Price Low Price Average Price
Nov-2025 16.99 13.71 14.64
Oct-2025 15.76 13.10 14.18
Sep-2025 16.99 14.03 15.12

Stock price at NSE (in preceding 3 months)

Month High Price Low Price Average Price
Jan-2025 293.00 247.00 267.21
Jan-2025 343.00 226.84 263.74
Jan-2025 278.40 226.00 246.80

Compare with others

Compare: